Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 7,073 matching trials from the live ClinicalTrials.gov search.
Conditions
Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer, Uterine Cancer, Renal Cell Cancer, Thymic Cancer
Interventions
Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer, Gastric Cancer
Interventions
margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Conditions
Advanced Solid Tumor
Interventions
STX-001, Keytruda®
Biological
Lead sponsor
Strand Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more
Conditions
Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions
RTX-224
Drug
Lead sponsor
Rubius Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 2 more
Conditions
Breast Cancer
Interventions
Crixotinib 200 mg and Sunitinib Cohort 1, Crixotinib 250 mg and Sunitinib Cohort 2, Crizotinib & Sunitinib 37.5 mg Cohort 3
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Ad-sig-hMUC-1/ecdCD40L vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Trastuzumab Deruxtecan, Datopotamab Deruxtecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more
Conditions
Breast Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Weight Changes
Interventions
exercise intervention, questionnaire administration, CAM exercise therapy, management of therapy complications, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma
Interventions
Olaparib, Hyperthermia Treatment, Questionnaire Administration, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
ChemoFX Assay
Other
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 21 more
Conditions
HER2 Expressing Solid Tumors
Interventions
Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202
Genetic
Lead sponsor
Vironexis Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 8 more
Conditions
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
Interventions
elacestrant, palbociclib, abemaciclib, ribociclib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Chicago, Illinois
Conditions
Breast Cancer
Interventions
Surveillance Brain MRI, Standard of Care Brain Imaging
Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Miami, Florida • Tampa, Florida
Conditions
Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Cancer Female, Adriamycin Toxicity
Interventions
10,000 steps, Usual Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm
Interventions
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Examining the Long-Term Risks of Oophorectomy

NCT00655447
Conditions
Coronary Heart Disease, Stroke, Breast Cancer, Ovarian Cancer, Cancer, Hip Fracture, Death
Interventions
Not listed
Lead sponsor
Parker, William H., M.D.
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
32,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1980 – 2004
U.S. locations
1
States / cities
Santa Monica, California
Conditions
PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
Interventions
RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more
Conditions
Breast Cancer
Interventions
A high-intensity interval exercise group, An Attention-Control Group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions
GTAEXS617, SoC
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more
Conditions
Breast Cancer
Interventions
Radiofrequency Ablation
Device
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 3 more
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Insomnia
Interventions
Cognitive Behavior Therapy for Insomnia, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Text Message-Based Navigation Intervention
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington